title: Clotrimazole as a Cancer Drug: A Short Review.
abstract: Although clotrimazole was first used against fungal infections, a body of research was later developed indicating that this drug has anticancer properties as well. The mechanism of action is based on the inhibition of mitochondrial-bound glycolytic enzymes and calmodulin, which starves cancer cells of energy. Clotrimazole and its derivatives have been shown to decrease rates of cancer cell proliferation, induce G1 phase arrest, and promote pro-apoptotic factors, which lead to cell death.
authors.affiliation: Department of Natural Sciences, Western New Mexico University, Silver City, NM, 88061, USA.
authors.forename: S
authors.initials: S
authors.lastname: Kadavakollu
authors.affiliation: Department of Natural Sciences, Western New Mexico University, Silver City, NM, 88061, USA.
authors.forename: C
authors.initials: C
authors.lastname: Stailey
authors.affiliation: Department of Natural Sciences, Western New Mexico University, Silver City, NM, 88061, USA.
authors.forename: C S
authors.initials: CS
authors.lastname: Kunapareddy
authors.affiliation: Department of Natural Sciences, Western New Mexico University, Silver City, NM, 88061, USA.
authors.forename: S
authors.initials: S
authors.lastname: White
keywords: Calmodulin; Clotrimazole; Hexokinase; Human melanoma
references.citation: Cell Biol Toxicol. 2013 Dec;29(6):431-43
references.pmid: 24272524
references.citation: J Inorg Biochem. 2011 Mar;105(3):400-9
references.pmid: 21421126
references.citation: Eur J Pharmacol. 1997 Jun 11;328(2-3):241-8
references.pmid: 9218707
references.citation: Arzneimittelforschung. 1972 Aug;22(8):1260-72
references.pmid: 4564742
references.citation: J Control Release. 2002 Jul 18;82(1):39-50
references.pmid: 12106975
references.citation: Biochem J. 1991 Jul 1;277 ( Pt 1):73-9
references.pmid: 1906712
references.citation: Exp Mol Pathol. 2009 Jun;86(3):174-9
references.pmid: 19454274
references.citation: J Neurosurg. 2005 Jul;103(1):79-86
references.pmid: 16121977
references.citation: Drug Dev Ind Pharm. 2005 May;31(4-5):375-83
references.pmid: 16093203
references.citation: Curr Med Chem. 2007;14(13):1437-57
references.pmid: 17584055
references.citation: Bioorg Med Chem Lett. 2004 Jan 19;14(2):347-50
references.pmid: 14698156
references.citation: Eur J Pharmacol. 1996 Oct 17;313(3):265-71
references.pmid: 8911923
references.citation: Farmaco. 2002 Nov;57(11):931-8
references.pmid: 12484542
references.citation: J Inorg Biochem. 2012 Sep;114:82-93
references.pmid: 22717722
references.citation: Mol Genet Metab. 2002 Jul;76(3):181-8
references.pmid: 12126931
references.citation: Pediatr Dermatol. 2002 Jan-Feb;19(1):78-81
references.pmid: 11860579
references.citation: Clin Oral Investig. 2015 Mar;19(2):467-73
references.pmid: 24867230
references.citation: J Pharmacol Exp Ther. 1995 Apr;273(1):266-72
references.pmid: 7714775
references.citation: J Physiol. 1992 Jan;445:537-48
references.pmid: 1323670
references.citation: J Exp Med. 2011 Feb 14;208(2):313-26
references.pmid: 21242296
references.citation: Eur J Med Chem. 2012 Aug;54:483-98
references.pmid: 22749640
references.citation: Bioorg Med Chem. 2011 Sep 15;19(18):5446-53
references.pmid: 21855351
references.citation: Int J Parasitol Drugs Drug Resist. 2012 Dec;2:236-242
references.pmid: 23277882
references.citation: Pharmazie. 2007 Oct;62(10 ):756-9
references.pmid: 18236780
references.citation: Curr Pharm Des. 2010 Jun;16(16):1813-25
references.pmid: 20337575
references.citation: Mol Genet Metab. 2005 Apr;84(4):354-62
references.pmid: 15781197
references.citation: Biol Pharm Bull. 2004 Mar;27(3):361-5
references.pmid: 14993803
references.citation: Oncotarget. 2013 Oct;4(10):1606-17
references.pmid: 24091475
references.citation: Arch Pharm Res. 2007 Feb;30(2):249-54
references.pmid: 17366748
references.citation: J Biol Chem. 2002 Mar 1;277(9):7610-8
references.pmid: 11751859
references.citation: Eur J Pharmacol. 1998 Jan 19;342(1):113-7
references.pmid: 9544799
references.citation: PLoS One. 2008 Mar 19;3(3):e1852
references.pmid: 18350175
references.citation: PLoS One. 2012;7(2):e30462
references.pmid: 22347377
references.citation: Anticancer Agents Med Chem. 2008 Aug;8(6):698-704
references.pmid: 18690830
references.citation: J Invest Dermatol. 1993 Mar;100(3):343-6
references.pmid: 8440921
references.citation: Anticancer Drugs. 2010 Oct;21(9):841-9
references.pmid: 20724915
references.citation: Blood. 2003 Mar 15;101(6):2412-8
references.pmid: 12433690
references.citation: Nat Med. 1995 Jun;1(6):534-40
references.pmid: 7585119
references.citation: J Med Chem. 2008 Feb 28;51(4):976-82
references.pmid: 18232633
references.citation: J Am Chem Soc. 2008 Aug 6;130(31):10274-81
references.pmid: 18611022
references.citation: Oncogene. 2006 Aug 7;25(34):4777-86
references.pmid: 16892090
references.citation: Eur J Pharmacol. 2002 Sep 20;451(3):227-35
references.pmid: 12242083
references.citation: J Am Chem Soc. 2011 May 4;133(17):6780-90
references.pmid: 21473622
references.citation: J Cell Physiol. 2013 Sep;228(9):1943-8
references.pmid: 23629924